Back by Popular Demand - KRAS G12C Mutation: An Emerging Biomarker for NSCLC Sponsored by Amgen

IE users – if you are experiencing issues trying to register for this webinar, please use Chrome, Safari or Firefox.

Tuesday, May 4, 2021
12:00 PM ET/9:00 AM PT

Program objectives
We invite you to join us for an event discussing the following topics:
• The evolution of biomarkers in NSCLC
KRAS and KRAS G12C prevalence information
• Diagnostic strategies and options for KRAS G12C testing
Dr Fesko and Dr Hooper will review the science behind the KRAS G12C emerging biomarker.
Yuri Fesko, MD
Chief Clinical Officer, Oncology Quest Diagnostics
Secaucus, New Jersey
Kari Hooper, MD
Pathologist, AmeriPath®/Quest Diagnostics; Department Chair, 
Integris Baptist Medical Center Oklahoma City, Oklahoma